Placental Problems in Early Pregnancy Associated with 5-Fold Increase in Risk of Obstetric and Fetal Disorders

Increased Cell Death and Reduced Growth Promoting Factors Linked to the Early Pathology of Preeclampsia, Restricted Fetal Growth, and Stillbirth, According to Research Published in The American Journal of Pathology

Philadelphia, PA, September 16, 2015 – First-trimester ultrasound scanning to pinpoint placental vascular disorders may be used to identify women at risk of developing serious obstetric complications. A new study in The American Journal of Pathology finds that patients with the highest degree of uterine artery blood flow resistance have an almost five-fold increased chance of developing preeclampsia, fetal growth restriction, or stillbirth than other pregnant women. Increased cell death and reduced insulin-like growth factor-2 (IGF2) expression were found to be possible causal factors of abnormal placental development.

“Study of the placenta after delivery has limited value since by that time the disease process has progressed to the point that delivery is indicated. If we are to institute treatments to ameliorate, or ideally prevent, the consequences of poor placentation, then an understanding of the pathophysiology in the first trimester is necessary,” explained Dr. Karin Leslie of the Fetal Medicine Unit of St George’s Hospital in London (UK).

A successful pregnancy requires the establishment of vascular connections between mother and embryo via the placenta, and failure to do so is associated with serious obstetric and fetal disorders. Placentation, which refers to the development of the placenta and attachment of the fetus to the uterus during pregnancy, partly requires remodeling of the maternal uterine spiral arteries. Uterine artery Doppler (UtAD) ultrasound can measure uterine artery blood flow, and high-resistance UtAD in the first trimester is associated with increased risk of placental complications.

Using UtAD ultrasound in ongoing pregnancies, participants were divided according to resistance index (RI) scores, with high-resistance defined as a mean RI > 95th percentile and normal RI as < 95th percentile. The researchers found that of 9,952 pregnancies, women with high RI had a 15% risk of preeclampsia compared with a 2.8% risk in women with normal RI. Women with high RI had a 24%
chance of developing a placental complication of pregnancy (preeclampsia, fetal growth restriction, or stillbirth) compared to women with normal RI, who had a 4.9% risk.

The researchers next analyzed placental tissue from women with high RI undergoing termination of pregnancy for nonmedical reasons and compared the findings to women with normal RI. Enrolled women were pregnant with one fetus with gestational age of 9 to 14 weeks and were attending the clinic for termination of pregnancy in the first trimester. Cases with fetal structural abnormalities or maternal conditions such as renal disease, connective tissue disease, cardiac disease, or diabetes were excluded from the study.

“We found evidence that first trimester pregnancies with high RI have differentially regulated placental gene expression, higher placental levels of cell death, and lower levels of IGF2 compared with normal RI pregnancies. These changes are apparent several months before the clinical consequences of placental insufficiency become evident,” noted Dr. Leslie. The investigators also measured antioxidant enzyme activity and found that glutathione peroxidase activity decreased and superoxide dismutase activity increased in placental tissue from high RI pregnancies.

Interestingly, the researchers had initially hypothesized that placental hypoxia and oxidative stress might be important contributors to poor placentation. However, no differences between the groups were observed, with both high and normal RI placenta showing evidence of hypoxia and oxidative stress as measured by expression of hypoxia inducible factor (HIF)-1α and -2α or heat shock protein (HSP)70, presence of nitrotyrosine residues, and lipid peroxidation. “Our data support the concept that in the first trimester low oxygen levels and mild oxidative stress are a normal physiological state,” stated lead investigator Dr. Judith Cartwright, of the Fetal Medicine Unit of Saint George’s Hospital in London (UK).

“Investigating the pathogenesis of the clinical consequences of poor placentation such as fetal growth restriction, preeclampsia, and stillbirth has traditionally been hampered by our inability to study these pregnancies in the first trimester, when the critical events for successful placental development occur,” added Dr. Cartwright. Although the research is still in its early stages, these results suggest that problems detected early in pregnancy could direct future studies toward specific therapeutic targets.

# # #

NOTES FOR EDITORS


This research was supported by the National Institute for Health Research Clinical Lectureship and Action Medical Research UK grant SP4577.

Full text of this study is available to credentialed journalists upon request; contact Eileen Leahy at 732-238-3628 or ajpmedia@elsevier.com. Journalists wishing to interview the author may contact the Communications team at St George’s Hospital at +44 (0)2087251139 or communications@sgul.ac.uk.

ABOUT THE AMERICAN JOURNAL OF PATHOLOGY

The American Journal of Pathology (http://ajp.amjpathol.org), official journal of the American Society for Investigative Pathology, seeks to publish high-quality, original papers on the cellular and molecular biology of disease. The editors accept manuscripts that advance basic and translational knowledge of the pathogenesis, classification, diagnosis, and mechanisms of disease, without preference for a specific analytic method. High priority is given to studies on human disease and relevant experimental
models using cellular, molecular, animal, biological, chemical, and immunological approaches in conjunction with morphology.

The leading global forum for reporting quality original research on cellular and molecular mechanisms of disease, *The American Journal of Pathology* is the most highly cited journal in Pathology – close to 40,000 cites in 2014 – with an Impact Factor of 4.591 and Eigenfactor of 0.06689 according to the 2014 *Journal Citation Reports®,* Thomson Reuters, 2015, and an h-index of 217 according to the 2014 *SCImago Journal and Country Rank.*

**ABOUT ELSEVIER**
Elsevier ([www.elsevier.com](http://www.elsevier.com)) is a world-leading provider of information solutions that enhance the performance of science, health, and technology professionals, empowering them to make better decisions, deliver better care, and sometimes make groundbreaking discoveries that advance the boundaries of knowledge and human progress. Elsevier provides web-based, digital solutions — among them ScienceDirect ([www.sciencedirect.com](http://www.sciencedirect.com)), Scopus ([www.scopus.com](http://www.scopus.com)), Elsevier Research Intelligence ([www.elsevier.com/research-intelligence](http://www.elsevier.com/research-intelligence)), and ClinicalKey ([www.clinicalkey.com](http://www.clinicalkey.com)) — and publishes over 2,500 journals, including *The Lancet* ([www.thelancet.com](http://www.thelancet.com)) and *Cell* ([www.cell.com](http://www.cell.com)), and more than 33,000 book titles, including a number of iconic reference works. Elsevier is part of RELX Group plc ([www.relxgroup.com](http://www.relxgroup.com)), a world-leading provider of information solutions for professional customers across industries. [www.elsevier.com](http://www.elsevier.com)